Vitamin K (PIVKA-II): When to Order This Test

What PIVKA-II Actually Measures

PIVKA-II detects an abnormal form of prothrombin that the liver produces when vitamin K is too low to complete a chemical step called gamma-carboxylation. Normal prothrombin requires vitamin K-dependent carboxylation of 10 glutamic acid residues on its Gla domain to bind calcium and participate in coagulation 1. When vitamin K is absent or blocked (as with warfarin), the liver still synthesizes prothrombin, but the under-carboxylated version, PIVKA-II, accumulates in the blood.

This makes PIVKA-II a more sensitive early indicator of vitamin K insufficiency than prothrombin time (PT) or INR. PT does not become abnormal until roughly 50% of functional prothrombin is depleted 2. PIVKA-II concentrations can rise within 48 to 72 hours of vitamin K restriction, days before the INR moves. A 2004 study in the American Journal of Clinical Nutrition demonstrated that healthy adults placed on a vitamin K-restricted diet (<10 mcg/day) showed measurable PIVKA-II elevations by day 3, while their PT values remained within reference range through day 7 2.

The distinction matters clinically. A patient with a normal INR but elevated PIVKA-II has subclinical vitamin K deficiency. Left unaddressed, that deficiency can progress to coagulopathy, impair osteocalcin carboxylation (affecting bone mineralization), and increase vascular calcification risk 3.

When Clinicians Order This Test

The three primary clinical scenarios for ordering PIVKA-II are vitamin K status assessment, hepatocellular carcinoma surveillance, and anticoagulation management.

Vitamin K deficiency workup. The Endocrine Society's 2011 clinical practice guideline on vitamin D and calcium notes that patients on chronic antibiotic therapy, those with fat malabsorption syndromes (celiac disease, Crohn's, short bowel syndrome, cystic fibrosis), and patients receiving total parenteral nutrition are at high risk for vitamin K depletion 4. PIVKA-II is the preferred functional assay in these populations because direct vitamin K1 (phylloquinone) serum measurement reflects only recent dietary intake, not tissue stores. As the 2022 International Society on Thrombosis and Haemostasis (ISTH) consensus stated: "Functional markers such as PIVKA-II and undercarboxylated osteocalcin provide a more accurate picture of vitamin K sufficiency at the tissue level than circulating phylloquinone alone" 5.

HCC surveillance. The American Association for the Study of Liver Diseases (AASLD) 2023 guidance on hepatocellular carcinoma surveillance recommends combining alpha-fetoprotein (AFP) with PIVKA-II (DCP) every six months for patients with cirrhosis 6. In a meta-analysis of 12 studies encompassing 3,567 patients, the combination of AFP and PIVKA-II achieved a sensitivity of 86% for early-stage HCC, compared with 63% for AFP alone 7.

Warfarin monitoring. PIVKA-II can confirm anticoagulant effect when INR results are inconsistent with clinical presentation. It is not a replacement for INR but serves as a verification tool.

Normal PIVKA-II Range and How to Interpret Results

Reference values depend on the assay platform. Most U.S. laboratories using the LUMIPULSE or ARCHITECT immunoassay report a normal cutoff of <2.0 ng/mL for healthy adults not taking vitamin K antagonists 8. Some international laboratories use milli-arbitrary units per milliliter (mAU/mL) with a cutoff of <40 mAU/mL.

Results fall into three interpretive categories. Values below the cutoff (<2.0 ng/mL) indicate adequate vitamin K-dependent carboxylation. Mildly elevated values (2.0 to 7.5 ng/mL) suggest subclinical vitamin K insufficiency or early deficiency, often seen in patients with marginal dietary intake, mild cholestasis, or short-course antibiotics that disrupt gut flora. Markedly elevated values (>7.5 ng/mL in a patient not on warfarin) raise concern for significant vitamin K deficiency, liver synthetic dysfunction, or hepatocellular carcinoma 6.

A useful clinical decision framework: if PIVKA-II is elevated and the patient is not on a vitamin K antagonist, the next step is to check liver function (ALT, AST, bilirubin, albumin) and order an abdominal ultrasound in patients with known liver disease. If liver function is normal, a trial of oral vitamin K supplementation (5 mg phytonadione daily for 2 weeks) followed by repeat PIVKA-II testing can differentiate dietary deficiency from occult hepatic pathology. Persistent elevation after repletion warrants hepatology referral.

What a High PIVKA-II Means

An elevated PIVKA-II in the absence of warfarin or other vitamin K antagonists carries a differential diagnosis that includes three broad categories.

Vitamin K deficiency is the most common cause. This can result from inadequate dietary intake (the adequate intake for vitamin K1 is 120 mcg/day for adult men and 90 mcg/day for adult women per the National Academies 9), fat malabsorption, prolonged antibiotic use that depletes menaquinone-producing gut bacteria, or cholestatic liver disease impairing bile salt-dependent vitamin K absorption. Neonates are particularly vulnerable. Vitamin K deficiency bleeding (VKDB) in newborns who do not receive prophylactic vitamin K at birth occurs at a rate of 4.4 to 7.2 per 100,000 births 10.

Hepatocellular carcinoma. HCC cells overproduce PIVKA-II independent of vitamin K status. In the GALAD score model (Gender, Age, AFP-L3, AFP, DCP), PIVKA-II/DCP is one of five variables, and the model achieves an AUROC of 0.95 for detecting HCC at any stage in a validation cohort of 6,834 patients 11.

Obstructive jaundice and cholestasis. Impaired bile flow reduces intestinal absorption of the fat-soluble vitamin K, leading to under-carboxylation. This elevation is generally correctable with parenteral vitamin K (10 mg IV phytonadione), which bypasses the need for enteral absorption.

Patients on warfarin will have elevated PIVKA-II by pharmacologic design. This is expected and does not represent pathology.

What a Low PIVKA-II Means

A low or undetectable PIVKA-II is the normal finding. It confirms that the liver has adequate vitamin K to fully carboxylate prothrombin. There is no clinical syndrome associated with "too low" PIVKA-II. A value below the assay's detection limit simply means vitamin K-dependent carboxylation is functioning properly.

One practical note: patients taking high-dose vitamin K supplements (often prescribed alongside warfarin to stabilize INR fluctuations, typically 100 to 200 mcg/day of K1) may have very low PIVKA-II values. This does not require intervention. It reflects effective supplementation.

How to Lower an Elevated PIVKA-II

Lowering PIVKA-II depends entirely on the cause of elevation.

For vitamin K deficiency, oral supplementation with phytonadione (vitamin K1) at 1 to 10 mg daily corrects PIVKA-II levels within 7 to 14 days in most patients. A randomized trial in 440 postmenopausal women showed that 1 mg/day of phytonadione reduced PIVKA-II by 50% at 2 weeks, with near-complete normalization by 4 weeks 12. Dietary sources rich in vitamin K1 include kale (817 mcg per cup cooked), spinach (888 mcg per cup cooked), and broccoli (220 mcg per cup cooked) 9.

For malabsorption syndromes, parenteral vitamin K (subcutaneous or intravenous) bypasses the GI tract. Patients with short bowel syndrome, cystic fibrosis, or chronic cholestasis may require ongoing parenteral supplementation at 10 mg weekly or monthly, adjusted by repeat PIVKA-II measurement 4.

For HCC-related elevation, treating the underlying malignancy (resection, ablation, transplantation, or systemic therapy with atezolizumab-bevacizumab per ASCO 2024 guidelines) is the only way to reduce PIVKA-II. Post-treatment PIVKA-II monitoring can detect recurrence. A study of 312 HCC patients who underwent curative resection found that failure of PIVKA-II to normalize within 4 weeks post-surgery predicted recurrence with 78% sensitivity 13.

How to Raise PIVKA-II (and Why You Would Not Want To)

Intentionally raising PIVKA-II has no clinical application. Higher PIVKA-II means more under-carboxylated prothrombin, which means impaired coagulation and increased bleeding risk. The only scenario where PIVKA-II rises by design is during warfarin therapy, where the drug's mechanism of action specifically inhibits the vitamin K epoxide reductase cycle, preventing carboxylation.

If a patient's PIVKA-II is low and their INR is subtherapeutic despite adequate warfarin dosing, the issue is usually warfarin resistance (CYP2C9 or VKORC1 polymorphisms), excessive dietary vitamin K intake, or drug interactions that accelerate warfarin metabolism 14. The solution is pharmacogenomic-guided dose adjustment, not attempting to raise PIVKA-II directly.

Populations That Benefit Most from PIVKA-II Testing

Routine PIVKA-II screening is not recommended for the general population. But specific groups derive clear clinical value from this test.

Patients with cirrhosis should receive PIVKA-II plus AFP every 6 months per AASLD surveillance guidelines 6. Approximately 2 to 8% of cirrhotic patients develop HCC annually, and early detection via biomarker surveillance reduces HCC-related mortality by 37% compared with no surveillance, according to a Cochrane meta-analysis 15.

Neonates at risk for VKDB. The American Academy of Pediatrics (AAP) recommends intramuscular vitamin K prophylaxis for all newborns. When parents decline the injection, serial PIVKA-II monitoring (at 48 hours and 1 week) can identify developing deficiency before clinical bleeding 10.

Patients on chronic broad-spectrum antibiotics (particularly fluoroquinolones and cephalosporins for >2 weeks) may develop menaquinone depletion. The 2019 Infectious Diseases Society of America (IDSA) antimicrobial stewardship guideline acknowledges vitamin K disruption as a secondary effect of prolonged antibiotic courses 16.

Bariatric surgery patients. Roux-en-Y gastric bypass reduces fat-soluble vitamin absorption. A prospective cohort of 232 post-RYGB patients found that 23% had elevated PIVKA-II at 12 months despite oral multivitamin supplementation, compared with 4% of sleeve gastrectomy patients 17.

Patients on long-term total parenteral nutrition require periodic PIVKA-II checks because TPN formulations contain variable and sometimes insufficient vitamin K. The American Society for Parenteral and Enteral Nutrition (ASPEN) recommends monitoring vitamin K status at baseline and every 3 months in chronic TPN patients 18.

Ordering Logistics and Practical Considerations

PIVKA-II testing requires a standard serum specimen collected in a red-top or gold-top (SST) tube. No fasting is strictly necessary, though lipemic samples can interfere with immunoassay platforms. The specimen should be centrifuged and separated within 2 hours, then stored at 2 to 8 degrees Celsius if not processed immediately. Most reference laboratories (Quest Diagnostics, LabCorp, Mayo Clinic Laboratories) offer PIVKA-II/DCP testing, with turnaround times of 3 to 7 business days.

Insurance coverage varies by indication. When ordered for HCC surveillance in documented cirrhosis patients, most payers cover PIVKA-II under diagnostic laboratory benefits. When ordered for nutritional assessment, coverage may require a prior authorization or a supporting ICD-10 code for vitamin K deficiency (E56.1) or malabsorption (K90.x).

The test should not be ordered in isolation for suspected vitamin K deficiency. A complete workup includes PT/INR, undercarboxylated osteocalcin (ucOC), and serum phylloquinone, with PIVKA-II serving as the most specific functional marker of hepatic vitamin K status. As noted by Dr. Sarah Booth, director of the Vitamin K Laboratory at the Jean Mayer USDA Human Nutrition Research Center: "PIVKA-II is the gold standard functional biomarker for hepatic vitamin K status because it reflects the biological consequence of deficiency, not just circulating levels" 2.

For patients already on warfarin, PIVKA-II testing adds no diagnostic value for assessing vitamin K nutritional status because warfarin pharmacologically elevates PIVKA-II regardless of dietary vitamin K intake.